Extendicare Inc. (TSE:EXE – Get Free Report) announced a monthly dividend on Monday, September 16th, Zacks reports. Stockholders of record on Monday, September 30th will be given a dividend of 0.04 per share on Tuesday, October 15th. This represents a $0.48 annualized dividend and a dividend yield of 5.17%. The ex-dividend date of this dividend is Monday, September 30th.
Extendicare Price Performance
Shares of TSE:EXE opened at C$9.28 on Wednesday. Extendicare has a one year low of C$5.75 and a one year high of C$9.48. The stock has a market cap of C$774.60 million, a PE ratio of 13.65 and a beta of 1.26. The business’s fifty day moving average price is C$8.11 and its two-hundred day moving average price is C$7.63. The company has a debt-to-equity ratio of 305.80, a quick ratio of 0.98 and a current ratio of 0.60.
Extendicare (TSE:EXE – Get Free Report) last released its quarterly earnings results on Monday, August 12th. The company reported C$0.29 earnings per share (EPS) for the quarter. Extendicare had a net margin of 4.28% and a return on equity of 60.00%. The company had revenue of C$348.48 million for the quarter, compared to analysts’ expectations of C$360.20 million.
Analysts Set New Price Targets
Check Out Our Latest Research Report on EXE
Extendicare Company Profile
Extendicare Inc, through its subsidiaries, provides care and services for seniors in Canada. The company offers long term care (LTC) services; and home health care services, such as nursing care, occupational, physical and speech therapy, and assistance with daily activities, as well as management, consulting, and other services to third parties.
See Also
- Five stocks we like better than Extendicare
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Spotlight on ZIM: Take Advantage of Shipping Stock Upside
- How to Evaluate a Stock Before Buying
- Seize the Opportunity: Beyond Meat’s New Steak Could Spark Growth
- Stock Sentiment Analysis: How it Works
- Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion?
Receive News & Ratings for Extendicare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Extendicare and related companies with MarketBeat.com's FREE daily email newsletter.